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High Prevalence of Fecal Carriage of Extended Spectrum
b-Lactamase-Producing Enterobacteriaceae
Among Newly HIV-Diagnosed Adults
in a Community Setting in Tanzania
Joel Manyahi,1–3 Sabrina John Moyo,1,3 Marit Gjerde Tellevik,2 Nina Langeland,1,2 and Bjørn Blomberg1,2
Colonization in HIV-infected populations with extended-spectrum b-lactamase-producing Enterobacteriaceae
(ESBL-PE) is particularly worrisome in low-income settings. This study describes the prevalence of ESBL-PE
carriage and associated risk factors among newly HIV-diagnosed adults in a community setting in Tanzania.
A total of 595 newly diagnosed HIV-positive adults with a median age of 35 years with interquartile range
(IQR) 29–42 years and a median CD4 count of 492 cells/mL (IQR 390–666 cells/mL) were recruited. Among
these, 194/595 (32.6%, 95% confidence interval [CI] 28.9–36.6) were ESBL-PE carriers. Participants with low
CD4 count (<350 cells/mL) had significantly higher prevalence of ESBL-PE carriage compared with those with
CD4 count ‡350 cells/mL (26/58, 44.8%, vs. 168/537, 31.3%, p = 0.04). Antibiotic use in last 4 weeks (odds
ratio [OR] 1.55, 95% CI 1.08–2.22, p = 0.02) and CD4 count <350 cells/mL (OR 1.78, 95% CI 1.03–3.09,
p = 0.04) were independent risk factors for fecal carriage of ESBL-PE. In total, 244 isolates of ESBL-PE were
isolated from 194 participants. Of these, 238/244 (97.5%) harbored blaCTX-M genes, with blaCTX-M-15 being
predominant (219/238 (92%), followed by blaCTX-M-27 (9/238 (3.8%), blaCTX-M-14 (8/238 (3.4%), blaCTX-M-55
(1/238), and blaCTX-M 211/3 (1/238). blaSHV-2a genes were detected in four isolates, whereas the blaSHV-12 gene
was detected in one isolate. Phenotypic carbapenemase-producing Enterobacteriaceae was detected in one HIV-
positive person with CD4 count 132 cells/mL. In conclusion prevalence of ESBL-PE carriage is high among
newly diagnosed HIV adults in Dar es Salaam, and is significantly associated antibiotic use and low CD4 count.
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Introduction
Individuals living with HIV are at risk not only ofclassical HIV-related opportunistic infections such as
pneumocystis pneumonia and tuberculosis, but also severe
infections caused by common bacterial pathogens such as
Escherichia coli, salmonella, pneumococci, and staphylo-
cocci.1–3 The World Health Organization (WHO) recognizes
antimicrobial resistance (AMR) in such bacterial infections
as a major threat to global health. Extended-spectrum b-
lactamase-producing Enterobacteriaceae (ESBL-PE) constitute
a particular challenge, as almost all are multidrug resistant.
Previously, infections due to ESBL producers were mainly a
health care-associated problem.4,5 However, ESBL-PE infec-
tions are now increasingly acquired in the community.6,7
In resource-constrained settings, ESBL-PE infections
are spread more easily due to deficient infection control,
whereas expensive reserve antibiotics such as carbapenems
and colistin are inaccessible. Consequently, infections caused
by ESBL-PE carries high mortality exceeding mortality out-
come of bacterial infections in the preantibiotic era.5,8
Colonization with ESBL-PE frequently precedes invasive
diseases.9,10 Fecal carriage of ESBL-PE could pose greater
risk in people living with HIV due to the increased risk of
severe bacterial infections.1,2 In Tanzania, studies have
documented high frequency of infections caused by ESBL-PE
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in hospitalized patients.5,11–13 ESBL-PE carriage is also
common in hospital settings, and carriage rates of 50% have
been documented in hospitalized children in Tanzania.14
Even in community settings, studies have documented ESBL-
PE carriage rates of 11–32% in healthy children15 and 17%
in healthy adults16 in the same country. Although high rates
(89.7%) of ESBL-PE carriage have been reported in hospi-
talized HIV positive children in Tanzania,14 others docu-
mented lower rates (14%) in HIV-infected children in the
community in Zimbabwe.17 To date, no community-based
studies from Africa have reported frequencies and risk factors
for ESBL-PE carriage among newly diagnosed HIV adults.
HIV is pandemic in sub-Saharan Africa, and Tanzania has
an estimated 1.4 million people aged between 15 and 64
years living with HIV.18 We designed this study aimed to
determine prevalence of fecal carriage of ESBL producers in
HIV-infected people in the community; and assess any in-
fluence of antibiotic use, hospitalization, and CD4 count on
fecal carriage of ESBL producers. The findings may help
develop strategies for reducing the burden of AMR in a
population at high risk of severe infections.
Materials and Methods
Study sites and study participants
Newly diagnosed HIV-infected adults with CD4 count of
‡350 cells/mL who had not yet started antiretroviral treatment
(ART) were recruited consecutively as part of a double-blinded
randomized clinical trial (RCT), CoTrimResist (Clinical-
Trials.gov identifier: NCT03087890) between April 2017
and May 2018. The study was performed in Dar es Salaam,
Tanzania, the largest city and economic capital of Tanzania.
Participants were residents of the main municipals of Dar es
Salaam city, namely Kinondoni, Temeke, Ilala, Ubungo,
and Kigamboni, and were recruited through six HIV care
and treatment clinics at Mwananyamala Hospital, Amana
Hospital, Temeke Hospital, Pastoral Activities and Services
for People with AIDS Dar es Salaam Archdiocese (PASADA),
Mbagala Hospital, and Mnazimmoja Hospital. In addition,
newly diagnosed HIV-infected adults with CD4 counts of
<350 cells/mL (n = 58) were recruited from the same Hospitals
during screening for eligibility to the RCT. This article reports
on the baseline data before interventions and treatment.
Data collection
Health workers recorded participants’ data such as de-
mographics and clinical parameters on tablet computers
using standardized electronic case report forms employing
the RedCAP system (Research Electronic Data Capture,
Vanderbilt University, Nashville, TN), which automatically
synchronizes study data to a central data server.
Screening for ESBL-
and carbapenemase-producing Enterobacteriaceae
From each participant, a rectal swab was collected and
transported in liquid Cary-Blair medium (Fecal Transwab,
MWE Co Bath Ltd., Corsham, United Kingdom) in a cool
box and maintained at 4C with icepack. Rectal swabs were
inoculated into brain heart infusion (BHI) broth and incu-
bated overnight at 37C. Two drops (0.1 mL) from BHI
broth were subcultured on CHROMID ESBL (BioMérieux,
Marcy l’Etoile, France) for screening of ESBL-PE,19 and
CHROMID CARBA SMART (BioMérieux) for combined
screening for carbapenemase-producing Enterobacteriaceae
(CPE) and OXA-48-producing Enterobacteriaceae. The
plates were incubated at 37C for 24 hours and bacterial
growth interpreted according to manufacturer’s instructions.
Molecular characterized strains harboring different combi-
nations of b-lactamases were used for quality control as
previously described.14
Bacterial isolates were identified by MALDI-TOF MS
using the Microflex LT instrument and MALDI Biotyper 3.1
software (Bruker Daltonics, Bremen, Germany).
PCR and sequencing for detection
and identification of ESBL genes
DNA was extracted by a rapid boiling procedure and stored at
-20C. Real-time PCR was used for detection of cefotaxime-
Munich (CTX-M) encoding genes using a LightCycler 480
Instrument II (Roche Diagnostics, Mannheim, Germany).
Forward primer CTXM-F 5¢-ATGTGCAGYACCAGTAAR
GT-3¢, and reverse primers CTXM-R1 5¢-TGGGTGAAGTAA
GTGACCAGA-3¢ and CTXM-R2 5¢-TGGGTAAARTAGG
TCACCAGA-3¢ (TIB Molbiol, Berlin, Germany), which target
a 595 bp internal region present in all the five different CTX-M
groups, were used as previously described.14 Each run included
positive and negative controls in duplicates. The PCR products
were sequenced using the same reverse primers as for PCR.
Sequencing was done using BigDye Terminator v1.1 Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA). Se-
quences were analyzed using the Basic Local Alignment
Search Tool program available at the website of the National
Center for Biotechnology Information.
For confirmation of ESBL producers, isolates negative for
CTX-M PCR were tested for the presence of blaSHV genes
as previously described by Kommedal et al.20
Statistical analysis
We used chi-square test to assess the proportions of fecal
carriage of ESBL producers by patient characteristics. We
analyzed the association between risk factors of interest
(antibiotic use, prior hospitalization, and low CD4 counts)
and fecal carriage of ESBL producers, adjusting for age,
gender, education status, district of residence, and study
sites (individual study sites). For each main exposure vari-
able, we assessed all potential confounders using both lo-
gistic regression and Mantel–Haenszel method, defining a
confounder as a factor that changes the effect size by ‡10%.
Effect modification of factor between different groups were
examined by Mantel–Haenszel method. A significance level
of 0.05 was used and all p-values refer to two-sided tests.
Statistical analysis was performed using STATA version 16
(College Station, TX).
Ethical approval and consent to participate
Ethical approval to conduct the study in Tanzania was
obtained from Muhimbili University of Heath and Allied
Sciences senate research and publication committee (Ref. No.
2015-10-27/Vol.X/54)—Muhimbili University of Health and
Allied Sciences, National Institute for Medical Research
(NIMR/HQ/R.8a/Vol.IX/2144)—Tanzania, Ministry of Health,
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Community development, Gender, Elderly, and Children. The
clinical trial was also registered by Tanzania Food and
Drugs Authority (TZ16CT007) and Clinical trial.org
(NCT03087890). In Norway, the study was approved by
the Regional Committee for Medical and Health Research
Ethics of Western Norway (REK2015/540). Informed written
consent was obtained from each of the study participants.
Results
Description of study participants
We recruited a total of 595 newly HIV-diagnosed adults
with a median age of 35 years with interquartile range (IQR)
29–42 years and a median CD4 count of 492 cells/mL with
IQR 390–666 cells/mL. Among these, 537 (90.2%) were
newly diagnosed HIV seropositive individuals with CD4
counts ‡350 cells/mL (median 518 IQR 413–687) and 58
(9.8%) were newly diagnosed HIV seropositive individuals
with CD4 counts of <350 cells/mL (median 159 IQR 61–
259). Out of 595, 451 (75.8%) were female and 233 (39.2%)
were aged between 30 and 39 years. The majority, 360/595
(60.5%), of the HIV seropositive individuals had WHO
stage 1 HIV disease. Although 64/595 (10.8%) of partici-
pants had been admitted to hospital within the last year, 191/
595 (31.7%) reported use of antibiotics during the last 4
weeks before enrollment (Table 1).
Prevalence of ESBL carriage and identification
of the bacterial isolates
The overall prevalence of fecal carriage of ESBL-PE was
194/595 (32.6%, 95% confidence interval [CI] 28.9–36.6),
and the proportions of carriage in subgroups are shown
in Table 2. The prevalence of fecal carriage of ESBL-PE
varied between study sites (Table 2). Participants with low
CD4 counts (<350 cells/mL) had significantly higher prev-
alence of ESBL-PE carriage than those with higher CD4
counts (44.8%, 26/58 vs. 31.3%, 168/537, p = 0.04).
A total of 244 isolates of Enterobacteriaceae were iso-
lated from 194 participants harboring ESBL-PE phenotypes.
The majority of participants, 74.2%, were colonized by a
single ESBL-PE isolate, whereas 50/194 (25.8%) had two
or more bacterial isolates. E. coli was the predominant mi-
crobe, 209/244 (85.7%), followed by Klebsiella pneumo-
niae, 33/244 (13.5%), and Enterobacter cloacae, 2/244
(0.8%). Patients with CD4 counts <350 cells/mL were more
likely to carry multiple isolates of ESBL-PE than those with
higher CD4 counts (15.5%, 9/58 vs. 6.9%, 37/537, p = 0.02).
One E. coli isolate was CPE and isolated from an HIV
participant with CD4 count 132 cells/mL.
ESBL genotypes
PCR confirmed ESBL genotype for 242/244 (99.2%) of
isolates with phenotypic ESBL-PE. The majority, 238 (97.5%),
harbored blaCTX-M encoding genes. The most predominant
blaCTX-M gene was blaCTX-M-15 (219/238, 92%), followed
by blaCTX-M-27 9/238 (3.8%), blaCTX-M-14 8/238 (3.4%),
blaCTX-M-55 (1/238), and blaCTX-M 211/3 (1/238). All
K. pneumoniae and E. cloacae isolates carried the blaCTX-M-15
gene only, whereas E. coli displayed a diversity of blaCTX-M
genes, including the ones mentioned earlier. BlaSHV-2a genes
were detected in two E. coli and two K. pneumonia, whereas
the blaSHV-12 gene was detected in one E. coli.
Predictors of ESBL producers
Among the main risk factors of interest, only antibiotic
use during the last 4 weeks (odds ratio [OR] 1.55, 95% CI
1.08–2.22, p = 0.02) and CD4 count <350 cells/mL (OR 1.78,
95% CI 1.03–3.09, p = 0.04) were independently associated
with fecal carriage of ESBL producers (Table 3). Prior
hospitalization during the last 1 year was not a significant
risk factor (OR 0.79, 95% CI 0.44–1.40, p = 0.41). The ef-
fect size of each risk factors did not change significantly
Table 1. (Clinical Demographics) Characteristics
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Education


























Hospital admission within last year
No 531 89.2
Yes 64 10.8
Antibiotic use last 4 weeks
No 404 67.9
Yes 191 32.1
PASADA, Pastoral Activities and Services for People with AIDS
Dar es Salaam Archdiocese.
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(>10%), whereas adjusting for the other main risk factors
and potential confounders and effect modifiers, that is, age,
gender, education status, district of residence, and study
sites (individual study site). Thus, we did not find any sig-
nificant confounders or effect modifiers.
Discussion
This first community-based study reports prevalence of
fecal carriage of ESBL-PE in almost one third (194/595,
32.6%) of individuals newly diagnosed with HIV in Dar es
Salaam. This rate of ESBL-PE fecal carriage is much
higher than found among adults with unknown HIV status
in community-based studies in Northern Tanzania (55/334,
16.5%, p < 0.001),16 Burkina Faso (22/101, 21.8%, p = 0.03),21
Gambia (28/565, 5.0%, p < 0.001),22 and Morocco (4/93, 4.3%,
p < 0.001).23 Although we are not aware of other community-
based studies from HIV-infected adults in Africa, there was
significantly lower ESBL-PE carriage rate (24/175 13.7%,
p < 0.001) in a community-based studies of HIV-infected
children in Zimbabwe.17 The high carriage rate observed in
our study could be attributed to several factors, including the
choice of screening technique employed. Our use of broth
enrichment of rectal swabs may have increased the yield in
detecting ESBL-PE colonization.24,25 In contrast, our use of
rectal swabs may have inferior sensitivity compared with
stool culture used in other studies.19
We observed that antibiotic use during the last 4 weeks was
a strong risk factor for fecal carriage of ESBL producers in
this cohort. In Tanzania, almost all antibiotics can be accessed
over the counter. Overuse of antibiotics and misuse of broad-
spectrum antibiotics, such as cephalosporins for trivial infec-
tions, are known to contribute to increasing AMR, including
ESBL-PE. In this setting, people with an undiagnosed HIV
infection are likely to opt for self-medication with antibiotics
for intercurrent infections and symptoms related to an, as yet,
unrecognized immunodeficiency. Such overuse of antibiotics
may partially explain the high prevalence of ESBL-PE carriage
in our study. This study confirms our hypothesis that antibiotic
use affects carriage of resistant bacteria in HIV populations,
and our finding is consistent with earlier observations from
community and hospital settings in Africa.14,16,21,22
Previous hospitalization is a well-known risk factor for
fecal carriage of ESBL producers,12,21 contributing both to
increased likelihood of antibiotics uses and acquisition of
ESBL producers in gastrointestinal tract. However, this study
could not add support this observation. Tanzania’s current
implementation of the ‘‘test and treat’’ strategy for HIV is
expected to result in more people getting diagnosed before
actually experiencing symptomatic disease. Despite this, it is











Female 451 32.6 (147)
Male 144 32.6 (47) 1.000
Age (years)
Up to 29 165 35.8 (59)
30–39 233 30.0 (70)
40–49 148 32.8 (50)
50–59 33 18.2 (6)
60 and above 16 56.3 (9) 0.068
Education
Primary school 388 30.2 (117)
Secondary 126 31.7 (40)
Postsecondary 24 50.0 (12)
None/informal 57 43.9 (25) 0.053
District of residence
Temeke 289 29.4 (85)
Kinondoni 114 38.6 (44)
Ubungo 32 34.4 (11)
Ilala 139 36.7 (51)
Kigamboni 12 0.0 (0)
Others 9 33.3 (3) 0.072
HIV stage
1 360 31.9 (115)
2 173 31.8 (55)
3 59 40.7 (24)
4 3 0.0 (0) 0.344
CD4 counts (cells/mL)
‡350 537 31.3 (168)
<350 58 44.8 (26) 0.037*
Study site
PASADA 168 22.0 (37)
Temeke 54 20.4 (11)
Amana 30 33.3 (10)
Mwananyamala 100 40.0 (40)
Mbagala 124 39.5 (49)
Mnazimmoja 119 39.5 (47) 0.001*
Hospital admission within last year
No 531 33.1 (176)
Yes 64 28.1 (18) 0.418
Antibiotic use last 4 weeks
No 404 29.5 (119)
Yes 191 39.3 (75) 0.017*
*p-Values calculated by chi-square test with 0.05 as cutoff for
statistical significance.
ESBL, extended-spectrum b-lactamase.
Table 3. Risk Factors for Fecal Carriage
of Extended-Spectrum b-Lactamase




% (n) OR 95% CI p
CD4 counts (cells/mL)*
‡350 537 31.3 (168) 1
<350 58 44.8 (26) 1.78 1.03–3.09 0.04
Antibiotic use last 4 weeks{
No 404 29.5 (119)
Yes 191 39.3 (75) 1.55 1.08–2.22 0.02
Hospital admission within last year
No 531 33.1 (176) 1
Yes 64 28.1 (18) 0.79 0.44–1.40 0.41
*Adjusted for antibiotic use in last 4 weeks, study sites, hospital
admission with last year, age, gender, and education status.
{Adjusting for age, gender, education status, hospital admission
within last year, CD4 count and study sites.
CI, confidence interval; OR, odds ratio.
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plausible that many patients will have consulted health care
services, without actually having been admitted, for un-
known HIV-related ailments before getting diagnosed with
HIV, and that this may have led to increased risks of gas-
trointestinal colonization with ESBL-PE.
This study found low CD4 count (<350 cells/mL) was an
independent risk factor for fecal carriage of ESBL. Low
immunity predisposes to risk of opportunistic infections
increasing the likelihood of antimicrobial use and hospi-
talization. However, adjustment for both antibiotic use and
hospitalization did not alter the independent association
between low CD count and fecal carriage of ESBL pro-
ducers. Furthermore, Wilmore et al.17 found no association
between low CD count and fecal carriage of ESBL pro-
ducers in children in Zimbabwe.17 The differences could
be explained by inclusion criteria, this study recruited
newly diagnosed HIV-infected adults not yet on ART,
whereas Wilmore et al. enrolled children who were stable
on ART.17
Our study confirmed blaCTX-M 15 as the predominant
ESBL gene type accounting 92% of all isolates, supporting
other reports on the extraordinary dissemination of the
blaCTX-M-15 genotype worldwide. In the first ever report of
ESBL-PE from Tanzania,5,13 we showed that blaCTX-M-15,
alongside TEM-63, was the dominant cause of ESBL-PE
bloodstream infections in Tanzania as early as 2001–2002.
Later on, we found predominance of blaCTX-M-15 in clinical
isolates from community-acquired urinary tract infections
from 2004 (Ref.7). Reports from elsewhere26,27 indicate that
when blaCTX-M-15 genotype penetrates in a new landscape
where other ESBL genes persist, blaCTX-M-15 tend to dis-
place other genes and becomes predominant. All recent
studies from community and hospital settings in Tanzania
have supported the predominance of blaCTX-M 15 genes
among Enterobacteriaceae isolated from feces.12,15,16 The
CTX-M group 9, blaCTX-M-27, and blaCTX-14 were also
documented in this study and were only isolated from E. coli.
This correlates with a recent study among HIV-infected
children in Zimbabwe.17 Our previous study on uropatho-
genic isolates did not detect any blaCTX-M group 9 genes,
7
whereas a pediatric study reported only two E. coli isolates
carrying blaCTX-M-14 genes and none with blaCTX-M-27.
14 In
conclusion, the study found a high prevalence of fecal
ESBL-PE carriage among people newly diagnosed with
HIV. Antibiotic use during the last 4 weeks and low CD4
count were risk factors for fecal carriage of ESBL producers.
Further studies should investigate transmission dynamics of
ESBL-PE in the community, complex factors driving the
emergence of multidrug-resistant bacteria, and the relation-
ship between ESBL-PE carriage and invasive disease. Social
behavior and policies on AMR need to be crafted and reg-
ulation on antimicrobial use must be enforced.
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